
Browsing restrictions can be lifted for a fee.
Concord Medical Co., Ltd. provides hospital management support services in Taiwan, Myanmar, and China. It offers medical management services that include medical training and nursing staffing, and assisting on medical management; and procurement services for equipment, drugs, medical materials and consumables, inspection equipment, and reagents and consumables, as well as develops its own brand for medical beauty care products, health foods, and finished Chinese medicine products. The company is also involved in the medical equipment planning and sales; and medical equipment leasing activities. Concord Medical Co., Ltd. was founded in 2009 and is based in New Taipei City, Taiwan.
6518
康科特
0.18%
(0.00)
The most recent financial report for 康科特 (6518) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6518's short-term business performance and financial health. For the latest updates on 6518's earnings releases, visit this page regularly.
According to historical valuation range analysis, 康科特 (6518)'s current price-to-earnings (P/E) ratio is 12.04, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 康科特 (6518) reported an Operating Profit of 35.71M with an Operating Margin of 7.96% this period, representing a growth of 24.01% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 康科特 (6518) announced revenue of 448.81M, with a Year-Over-Year growth rate of 3.57%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 康科特 (6518) held Total Cash and Cash Equivalents of 169.65M, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 康科特 (6518) achieved the “three margins increasing” benchmark, with a gross margin of 13.67%%, operating margin of 7.96%%, and net margin of 6.44%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6518's profit trajectory and future growth potential.
According to the past four quarterly reports, 康科特 (6518)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.87. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
康科特 (6518)'s Free Cash Flow (FCF) for the period is 110.11M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 106.35% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.